Axio Research Corporation   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Seattle WA United States (1979)

Organization Overview

First Clinical Trial
2005
NCT00120289
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

Axio Research Corporation | Axio Research. LLC

Active Ingredients

Drugs in Phase 4 Trials (2)

edoxaban (savaysa) (1 trial)

warfarin (coumadin) (1 trial)

Drugs in Phase 3 Trials (2)

niacin (1 trial)

simvastatin (zocor) (1 trial)

Drugs in Phase 2 Trials (1)

vatiquinone (1 trial)

Drugs in Phase 1 Trials (1)

Tetanus and diphtheria toxoids adsorbed (Decavac) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atherosclerosis (Phase 3)

Atrial Fibrillation (Phase 4)

Cardiovascular Diseases (Phase 3)

Coronary Disease (Phase 3)

Diphtheria (Phase 1)

Heart Diseases (Phase 3)

Infarction (Phase 3)

Leigh Disease (Phase 2)

Myocardial Infarction (Phase 3)

Stroke (Phase 3)

Syndrome (Phase 2)

Tetanus (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 6